Publication of combined circular and prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN OR SOUTH AFRICA.

THE CONTENTS OF THIS ANNOUNCEMENT DO NOT CONSTITUTE OR FORM PART OF AN OFFER OF OR INVITATION TO SELL OR ISSUE OR ANY SOLICITATION OF ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES FOR SALE IN ANY JURISDICTION NOR SHALL THEY (OR ANY PART OF THEM) OR THE FACT OF THEIR DISTRIBUTION FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY CONTRACT OR COMMITMENT TO DO SO.  THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS FOR THE PURPOSES OF EU DIRECTIVE 2003/71/EC (THE “DIRECTIVE”) AND PART VI OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 AS AMENDED.  A PROSPECTUS WILL BE PREPARED AND MADE AVAILABLE TO THE PUBLIC IN ACCORDANCE WITH THE DIRECTIVE.  RECIPIENTS OF THIS ANNOUNCEMENT WHO INTEND TO PURCHASE SUCH SECURITIES ARE REMINDED THAT ANY SUCH PURCHASE OR SUBSCRIPTION MUST BE MADE SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS IN ITS FINAL FORM.

THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION.  NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES.

 

10 February 2012

 

PUBLICATION OF COMBINED CIRCULAR AND PROSPECTUS

 

Further to the announcement today by Vernalis plc (LSE: VER) of the fully underwritten Firm Placing and Placing and Open Offer of 342,528,564 New Ordinary Shares at 20 pence per share raising £65.9 million (net of expenses) and a waiver of the obligations under Rule 9 of the Takeover Code (all of which remain subject to approval by shareholders at a General Meeting to be held on 28 February 2012), Vernalis announces that a Combined Circular and Prospectus in relation to the Firm Placing and Placing and Open Offer and waiver of obligations under Rule 9 of the Takeover Code (the "Prospectus") has been published and will be posted to shareholders shortly.

 

The Prospectus has been approved by the FSA, has been submitted to the National Storage Mechanism and will be available for inspection at www.hemscott.com/nsm.do.

 

The Prospectus is also available on the Investor Centre page of the Company's website at www.vernalis.com.

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.  Your right to access this service is conditional upon complying with the above requirement.

 

 

-- ends --

 

Enquiries:

Vernalis plc

+44 (0) 118 989 9360

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

Brunswick Group

+44 (0) 20 7404 5959

Jon Coles

Kristin Shine

Taylor Rafferty

+44 (0) 20 7614 2900

Rob Newman

Faisal Kanth

 

 

Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch